In work led by Dr. Steve Nordeen at the University of Colorado Anschutz Medical Campus, researchers have been studying flavones – molecules commonly found in fruits, vegetables and other plants. Flavones are often associated with the benefits of plant-rich diets, but they can also interact with the body’s hormone systems in complex ways. Nordeen and his team set out to understand exactly how these compounds affect key hormone receptors, including those involved in estrogen signaling.

Their earlier laboratory studies revealed an important pattern. Many flavones can weakly activate estrogen receptors, while some can block other hormone pathways such as androgen or progesterone signaling. Crucially, Nordeen’s group showed that tiny changes in the chemical structure of these molecules can dramatically alter how they behave in cells. That insight opened the door to something more ambitious: designing improved versions of flavones with specific, useful properties.

Using this structure-guided approach, the team created a new synthetic flavone simply termed 3F. In cell studies, this compound showed stronger estrogen-like activity than naturally occurring flavones. Rather than stopping there, the researchers asked whether this molecule might have practical medical value, particularly for conditions where local estrogen effects are helpful.

Their more recent work focused on vaginal atrophy, a common menopausal condition in which vaginal tissue becomes thinner, drier and more fragile. In preclinical models, topical treatment with the engineered flavone produced striking results. The compound stimulated changes typically associated with healthy, pre-menopausal vaginal tissue, including improved tissue structure and increased production of both lubricating and anti-microbial proteins.

Although some of the compound entered the circulation, the strongest effects remained concentrated in the vaginal tissue. Because the flavone is far less potent than the body’s natural estrogen and is rapidly broken down by the body, the researchers found no evidence of estrogenic effects in the uterus – one of the body’s most estrogen-sensitive tissues. That combination of strong local benefit with minimal activity elsewhere in the body is exactly what many researchers have been hoping to achieve.

Nordeen’s research highlights a promising strategy: starting with molecules found in nature, carefully mapping how they interact with hormone systems, and then redesigning them into more precise treatments. If clinical studies confirm these early findings, flavone-based therapies could offer a new option for managing menopausal symptoms more safely and comfortably.